We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BioLineRx Presents Data Demonstrating the Potential for BL-1020 to Improve Cognitive Deficits in Preclinical Models
News

BioLineRx Presents Data Demonstrating the Potential for BL-1020 to Improve Cognitive Deficits in Preclinical Models

BioLineRx Presents Data Demonstrating the Potential for BL-1020 to Improve Cognitive Deficits in Preclinical Models
News

BioLineRx Presents Data Demonstrating the Potential for BL-1020 to Improve Cognitive Deficits in Preclinical Models

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioLineRx Presents Data Demonstrating the Potential for BL-1020 to Improve Cognitive Deficits in Preclinical Models"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioLineRx Ltd. has announced that data from preclinical behavioral models of BL-1020, a GABA-enhanced antipsychotic for the treatment of schizophrenia, were presented at the Society of Biological Psychiatry (SOBP) 64rd Annual Scientific Convention & Meeting held in Vancouver, Canada May 14-16, 2009.

Recent data demonstrate that BL-1020 can repair chronic cognitive deficits in animal models, potentially via enhanced dopamine release in the pre-frontal cortex. Dr. Jo Neill, Professor of Psychopharmacology, at the School of Pharmacy, University of Bradford in UK, has presented the findings.

”We are pleased to present these data at this important psychiatric conference. The potential of improving cognition addresses the unmet medical need in schizophrenia and supports our target product profile of developing a highly efficacious antipsychotic without compliance limiting extrapyramidal or metabolic side effects with the potential to improve cognition,” commented Morris C. Laster, MD, chief executive officer of BioLineRx.

“We believe that the compound holds great promise for the treatment of schizophrenia, and are pleased to report that the ISMB has reviewed the safety data of the first 200 patients who completed the 6 week trial and did not report any safety concerns related to the trial. We are eagerly awaiting the results of our phase IIb EAGLE trial expected in Q3 of 2009”
Advertisement